When should I start treatment for HER2-Positive Breast Cancer vs watchful waiting

HER2-Positive Breast Cancer: Treatment Timing vs. Watchful Waiting

This is an excellent and nuanced question that many HER2-positive breast cancer patients face. Let me walk you through how doctors think about this decision and what the current evidence shows.

How Doctors Approach This Decision

According to expert perspectives shared in the CancerPatientLab webinars, the decision between starting treatment immediately versus monitoring depends on several key factors:

The Clinical Framework: Doctors typically consider:

• Stage of disease (early-stage vs. metastatic)
• Tumor burden (how much cancer is present)
• Doubling time (how fast the cancer is growing)
• Your overall health and preferences
• Whether you have detectable circulating tumor DNA (ctDNA)

What the Evidence Shows

For Early-Stage HER2-Positive Breast Cancer

Standard approach: Most patients with early-stage HER2-positive breast cancer receive adjuvant therapy (treatment after surgery to prevent recurrence). This typically includes:

• Anti-HER2 targeted therapies (like trastuzumab/Herceptin)
• Often combined with chemotherapy
• CDK4/6 inhibitors (like palbociclib) in certain situations

According to the webinar discussion with Dr. [removed] Lopez-Correa, MD, PhD, who navigated her own HER2-positive breast cancer diagnosis, the standard of care for early-stage disease generally involves completing recommended adjuvant treatment rather than watchful waiting.

The Role of Circulating Tumor DNA (ctDNA) Testing

This is where the timing question becomes more sophisticated. Dr. [removed]-Correa discusses an emerging approach:

If ctDNA is undetectable after initial treatment:

• Some doctors may recommend active surveillance (careful monitoring) rather than extended treatment
• This involves regular imaging and clinical exams
• Treatment can be restarted if ctDNA becomes detectable or imaging shows progression

If ctDNA remains detectable:

• This may suggest continuing or intensifying treatment
• Your doctor may recommend additional therapy to eliminate remaining cancer cells

Important caveat: As Dr. [removed]-Correa notes, ctDNA testing (like Signatera) is still evolving. While it can provide valuable information about tumor burden and doubling time, it's not yet standard practice to change treatment based solely on ctDNA results in all cases.

The "Active Surveillance" Concept

An important emerging concept in breast cancer care is active surveillance — carefully monitoring cancer without immediate treatment. According to the webinar discussions:

When active surveillance might be considered:

• Very slow-growing tumors (long doubling time of 1.5-2 years or more)
• Undetectable or very low disease burden
• Patient preference for delaying treatment side effects

The monitoring approach includes:

• Regular clinical exams and imaging (CT scans, breast exams)
• Periodic ctDNA testing to track tumor burden
• Clear plan to start treatment if cancer shows signs of acceleration

Real-world example: The webinars reference Olivia Newton-John, who lived 35-40 years after her breast cancer diagnosis before it became life-threatening — illustrating that some cancers grow very slowly and may not require immediate aggressive treatment.

Key Questions to Ask Your Oncologist

Since YOUR specific situation requires your doctor's evaluation, here are critical questions to guide your discussion:

1. What is my stage and specific HER2 status? (HER2-positive can vary in intensity — is it 3+ or 2+?)

2. What does the standard of care recommend for my specific situation? (Early-stage vs. metastatic changes the approach significantly)

3. Do you recommend ctDNA testing, and if so, how would the results change my treatment plan?

4. What is the estimated doubling time of my cancer based on imaging and pathology?

5. If I complete initial adjuvant therapy and ctDNA becomes undetectable, would active surveillance be an option, or do you recommend continuing treatment?

6. What are the side effects of the treatments you're recommending, and how do they compare to the benefit?

7. Are there clinical trials available that might be appropriate for my situation?

Important Context About Treatment Decisions

The webinar experts emphasize that treatment decisions should involve shared decision-making — meaning your values, preferences, and life circumstances matter alongside the medical evidence. As Dr. [removed]-Correa notes, patients need to consider not just clinical utility but also "planning your life as a patient" — what you want to do today, tomorrow, and in coming months.

However, they also note that patients often want to pursue treatment when diagnosed with cancer, even when watchful waiting might be appropriate. The key is having an honest conversation with your oncologist about:

• What the evidence actually shows for YOUR specific situation
• What "watchful waiting" really means (it's not doing nothing — it's active monitoring)
• When treatment would be started if needed

Current Medical Guidelines

According to the webinar discussions referencing HER2-positive breast cancer management, anti-HER2 therapies (particularly trastuzumab and newer agents like trastuzumab deruxtecan/Enhertu) have become central to treatment because HER2 drives cancer cell proliferation. The question isn't usually whether to use these therapies, but rather when and in what combination.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your oncologist will determine the most appropriate approach for YOUR specific case based on your complete clinical picture, pathology findings, imaging results, and personal circumstances.